Seelos Therapeutics, Inc. (NXE0.F)

2.0000 0.0000 (0.00%) 收市：08:01AM CEST

Seelos Therapeutics, Inc.

300 Park Avenue
2nd Floor
New York, NY 10022
United States
646 293 2100
https://seelostherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 10

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Raj Mehra J.D., Ph.D.	CEO, Founder, President & Director	559.31k	無	1960
Mr. Michael J. Golembiewski	Chief Financial Officer	362.16k	無	1972
Mr. Anthony Marciano	Chief Communications Officer	無	無	無
Gopal Krishna Ph.D.	Head of Manufacturing & Technical Operations	無	無	無
Tim Whitaker M.D.	Chief Medical Officer	無	無	無
Ms. Karen Fusaro	Senior VP & Head of Clinical Operations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

公司管治

截至 無 止，Seelos Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。